TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03617341

Intervention type: PROCEDURE
Intervention: Brain MRI
Description: Brain MRI will be taken at the time of initial diagnosis, first- and second-line treatment failure. Therefore, the investigators expect that early detection of brain metastases before the onset of symptoms will affect the overall prognosis of MBC patients.
Study: NCT05576194

Intervention type: DEVICE
Intervention: TauroPace
Description: All the hardware (leads, suture sleeves, pulse generator) is washed and the device pocket irrigated with an adjunct antimicrobial solution containing Taurolidine (TauroPace™, Tauropharm, Bavaria, Germany), during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system since January 2019

Intervention type: DEVICE
Intervention: TauroPace
Description: All the hardware (leads, suture sleeves, pulse generator) is washed and the device pocket irrigated with an adjunct antimicrobial solution containing Taurolidine (TauroPace™, Tauropharm, Bavaria, Germany), during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system since January 2019

Intervention type: DEVICE
Intervention: Hydrogen Peroxide
Description: All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing 3% hydrogen peroxide (H2O2) during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2020

Intervention type: DRUG
Intervention: Taurolidine
Description: All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing taurolidine in a galenic formulation during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2019
Study: NCT03207100

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Analgesia-first minimal sedation
Description: Remifentanil will be administered by IV infusion and maintained at a dose of 0.025 μg/kg/min in non-mechanically ventilated patients and a dose of 0.05 μg/kg/min in mechanically ventilated patients. BP will be measured after 10 min of continuous infusion.If systolic BP is still ≥ 140 mmHg, then dexmedetomidine will be applied using an infusion pump at a dose of 0.2 μg/kg/h. BP will be measured again after 15 min of continuous infusion of dexmedetomidine. If systolic BP is still ≥ 140 mmHg, the dose of dexmedetomidine can be increased 0.1 μg/kg/h to the maximum of 0.6 μg/kg/h.If the maximum dose of dexmedetomidine does not lower blood pressure, use routine blood pressure reduction programs in each center to reduce blood pressure to the target range. Mechanically ventilated patients will be given a rapid remifentanil (0.5 μg/kg) infusion to reduce procedure-related pain.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive treatment
Description: Routine antihypertensive treatment will be performed in accordance with the protocol of each respective research center. Urapidil, nicardipine, and labetalol will be used in this group. Urapidil will be used as follows: a slow IV injection of 10-15 mg and then IV pumping for maintenance at an initial rate of 2 mg/min, adjusted according to BP to a maximum of 9 mg/min. Nicardipine will be used as follows: IV pumping at 0.5μg/kg/min adjusted according to BP to a maximum of 6μg/kg/min. Labetalol will be used as follows: IV infusion for maintenance at 1-4 mg/min until the aim is reached.The mechanically ventilated patients in the control group will be administered a rapid physiological saline infusion as a controlled pretreatment.
Study: NCT02038491

Intervention type: PROCEDURE
Intervention: regional anesthesia
Description: Spinal, epidural, combined spinal epidural, nerve blocks
Study: NCT03728777

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol supplementation 1000 mg /day or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol supplementation 1000 mg /day or placebo
Study: NCT04407585

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 swab PCR test
Description: Participants satisfying machine learning test criteria will be asked to take a swab test for Covid-19.
Study: NCT03717129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genvoya Oral dose
Description: Single Genvoya oral dose directly observed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya Crushed Dose
Description: Single Genvoya crushed tablet in water directly observed
Study: NCT01822288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone
Description: Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol & medroxyprogesterone acetate
Description: Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
Study: NCT00603720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NAME
Description: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-NAME
Description: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: aids in nitric oxide production

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: aids in nitric oxide production

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: alpha agonist; 10 μg/kg/min infusion during PET study
Study: NCT02889003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone + TKI
Study: NCT01847053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cinnamon
Description: Intervention will be both ground cinnamon and cinnamon extract.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cinnamon
Description: Intervention will be both ground cinnamon and cinnamon extract.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cinnamon
Description: Intervention will be both ground cinnamon and cinnamon extract.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oatmeal
Description: Oatmeal control, around 70g; without cinnamon
Study: NCT02020382

Intervention type: DEVICE
Group type: OTHER
Intervention: qPCR diagnostic KIT of microRNAS
Description: testing qPCR diagnostic KIT of microRNAS from colonic biopsies

Intervention type: DEVICE
Group type: OTHER
Intervention: qPCR diagnostic KIT of microRNAS
Description: testing qPCR diagnostic KIT of microRNAS from colonic biopsies

Intervention type: DEVICE
Group type: OTHER
Intervention: qPCR diagnostic KIT of microRNAS
Description: testing qPCR diagnostic KIT of microRNAS from colonic biopsies

Intervention type: DEVICE
Group type: OTHER
Intervention: qPCR diagnostic KIT of microRNAS
Description: testing qPCR diagnostic KIT of microRNAS from colonic biopsies

Intervention type: DEVICE
Group type: OTHER
Intervention: qPCR diagnostic KIT of microRNAS
Description: testing qPCR diagnostic KIT of microRNAS from colonic biopsies

Intervention type: DEVICE
Group type: OTHER
Intervention: qPCR diagnostic KIT of microRNAS
Description: testing qPCR diagnostic KIT of microRNAS from colonic biopsies
Study: NCT04870853

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records reviewed
Study: NCT03753620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: simultaneous fMRI and EEG + peripheral measures
Description: Hemodynamic activity recorded with fMRI, cerebral electric activity recorded with EEG as well as peripheral physiological parameters will be recorded during music listening.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG and peripheral measures
Description: cerebral electric( with EEG) as well as peripheral physiological parameters will be recorded during music listening.
Study: NCT00368160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: eszopiclone 3 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT02940821

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing
Description: Mechanical plaque removal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing
Description: Mechanical plaque removal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing
Description: Mechanical plaque removal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoridated Dentifrice (.15% sodium monofluorophosphate)
Description: Fluoridated dentifrice application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)
Description: Application of Tooth Whitening Agent in Dentifrice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whitening (4.5% hydrogen peroxide)
Description: Application of Whitening Agent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other Fluoridated Dentifrice (.454% stannous fluoride)
Description: Fluoridated dentifrice application
Study: NCT01828788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04168684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC)
Description: Manualized intervention implemented in home with parent and child present focused on parental responsiveness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education for Families (DEF)
Description: Manualized intervention implemented in home with parent and child present focused on parental enhancement of child learning
Study: NCT00890487

Intervention type: OTHER
Group type: OTHER
Intervention: hyaluronic acid pill
Description: pill, 220 mg, once a day, three months
Study: NCT04543487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Description: Therapeutic touch was applied twice to the women in the intervention group in addition to routine practices. The first application was performed in the active phase of the first stage of labour, and the second was done in the second stage of labour.
Study: NCT01724073

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leafy vegetable-fish sauce

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leafy vegetable-fish/liver sauce

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Misola
Study: NCT03272126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D given as bolus versus daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D given as bolus versus daily dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical looking as vitamin D
Study: NCT03111121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: receive reversal with sugammadex 4mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: receive reversal with neostigmine 0.04 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycopyrrolate
Description: receive reversal with glycopyrrolate (0.01 mg/kg)
Study: NCT02482077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+RBV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+RBV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
Study: NCT00777946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren 300 mg
Description: Aliskiren 300 mg tablet taken orally once a day with a glass of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine 300/5 mg
Description: Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine 300/10 mg
Description: Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Aliskiren
Description: Placebo to Aliskiren tablet taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Aliskiren
Description: Placebo to Aliskiren tablet taken orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Aliskiren/Amlodipine
Description: Placebo to Aliskiren/Amlodipine taken orally once a day.
Study: NCT02684357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: Ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for ustekinumab
Description: Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for ustekinumab
Description: Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
Study: NCT01853982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Study: NCT04558749

Intervention type: OTHER
Intervention: State-trait anxiety inventory scale
Description: This scale is composed of two parts, part one measures anxiety traits and part two measures anxiety state. Each part comprises 20 statements. This scale is a (4) point scale, with a score ranging a minimum of 20 grades to a maximum of 80 grades.

Intervention type: OTHER
Intervention: Edinburgh Postnatal Depression Scale (EDPS)
Description: The EPDS is a self-report measure that focuses on the cognitive symptoms of depression. It excludes somatic items that might generate false positives both during pregnancy and after childbirth.7 The EPDS consists of 10 items, each scored 0-3 points, with a potential scale score of 0-30.
Study: NCT01300962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMK120
Description: BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMK120
Description: BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMK120
Description: BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab infusion on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: lapatinib daily for 21 days in each cycle.
Study: NCT00907790

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care (Control Group)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Self-Management (CSM)
Description: Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
Study: NCT00436033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milnacipran

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01658826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIC316
Description: 100 mg oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIC316
Description: 100 mg oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 500 mg oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 500 mg oral administration
Study: NCT00475033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Description: 7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
Study: NCT01315496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G
Description: Immunoglobulin 1.5-2g/Kg/3days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immunoglobulin G
Description: Immunoglobulin 1.5-2g/Kg/3days
Study: NCT04025567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: 1,500 mg total daily dose, on days 1-21 of every 28 days cycle.
Study: NCT03868488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery tasks
Description: All participants need to finish both visual imagery tasks and auditory imagery tasks. Visual imagery tasks and auditory imagery tasks will be carried out at intervals to avoid the influence of different tasks. The sequence of imagery tasks will be counterbalanced across participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery tasks
Description: All participants need to finish both visual imagery tasks and auditory imagery tasks. Visual imagery tasks and auditory imagery tasks will be carried out at intervals to avoid the influence of different tasks. The sequence of imagery tasks will be counterbalanced across participants.
Study: NCT04790019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy availability
Description: Participants will be provided with food to eat every day and will not be permitted to consume any other calorie containing foods or beverages. This amount of energy contained within the food provided will be one third of that contained in the food provided in the control condition (45 kilo-calories per kilogram of fat-free mass per day) and will be standardized between and within participants for carbohydrate, protein and fat composition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy availability
Description: Participants will be provided with food to eat every day and will not be permitted to consume any other calorie containing foods or beverages. This amount of energy contained within the food provided will be one third of that contained in the food provided in the control condition (45 kilo-calories per kilogram of fat-free mass per day) and will be standardized between and within participants for carbohydrate, protein and fat composition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High impact jumping
Description: Participants will perform a brief session of high impact jumping every morning (10 maximum effort vertical counter-movement jumps, and 5 maximum effort lateral drop jumps in each direction) and a similar session of high impact jumping every evening (20 maximum effort vertical counter-movement jumps).
Study: NCT03794570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction therapy - with Delfi Personalized Tourniquet System
Description: Physical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System
Description: Physical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure